Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cash from Financing Activities (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Cash from Financing Activities data on record, last reported at -$1.8 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 99.23% year-over-year to -$1.8 million; the TTM value through Dec 2025 reached -$16.5 million, up 93.0%, while the annual FY2025 figure was -$16.5 million, 93.0% up from the prior year.
  • Cash from Financing Activities reached -$1.8 million in Q4 2025 per MRVI's latest filing, up from -$8.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $809000.0 in Q3 2024 and bottomed at -$236.2 million in Q4 2024.
  • Average Cash from Financing Activities over 5 years is -$33.0 million, with a median of -$21.6 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 102.09% in 2023, then crashed 50352.98% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$49.6 million in 2021, then tumbled by 33.37% to -$66.1 million in 2022, then soared by 100.71% to $470000.0 in 2023, then plummeted by 50352.98% to -$236.2 million in 2024, then skyrocketed by 99.23% to -$1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$1.8 million in Q4 2025, -$8.2 million in Q3 2025, and -$1.5 million in Q2 2025.